Skip to main content

Table 1 Comparison of key subgroups in Checkmate 141 and KEYNOTE 040 trials

From: Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)

  Nivolumab SOC SOC Pembrolizumab
n = 240 n = 121 n = 248 n = 247
≥3 prior lines 19,9 1,2
PD-L1 TPS ≥ 1% (%) 37,0 50,0 77,0 79,4
PD-L1 TPS ≥ 50% (%) 26,2 25,9
HPV+ (%) 26,0 24,0 23,4 24,7
ECOG-0 (%) 20,0 19,0 17,0 19,0
ORR (%) 13,0 6,0 10,1 14,6
mPFS (mo.) 2,0 2,3 2,3 2,1
OS HR (CI95%) 0,70 (0,51-0,96) 0,80 (0,65-0,98)
  P = 0,01 P = 0,0161
mOS (mo.) 7,5 5,1 6,9 8,4
1y-OS rate 0,4 0,2 0,3 0,4